Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?

The vascular endothelial growth factor (VEGF) family includes key mediators of vasculogenesis and angiogenesis. VEGFs are secreted by various cells of epithelial and mesenchymal origin and by some immune cells in response to physiological and pathological stimuli. In addition, immune cells express V...

Full description

Saved in:

Bibliographic Details
Main Authors:	Cristina Maria Failla, Maria Luigia Carbone, Carmela Ramondino, Emanuele Bruni, Angela Orecchia
Format:	Article
Language:	English
Published:	MDPI AG 2024-12-01
Series:	Biomedicines
Subjects:	vascular angiogenic growth factor immune cells tyrosine kinase inhibitor immunotherapy angiogenesis
Online Access:	https://www.mdpi.com/2227-9059/13/1/6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Anti-angiogenic tyrosine kinase inhibitors and the pathophysiology of their toxic effects: revisiting the treatment of anemia in metastatic cancers
by: Tai Van Nguyen, et al.
Published: (2025-04-01)

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01)

Effect of the Vascular Endothelial Growth Factor Inhibitor Toceranib on Cardiac Function and Endothelial Dysfunction Biomarkers in Dogs With Cancer
by: Katherine E. Lopez, et al.
Published: (2025-05-01)

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database
by: Zongwei Tang, et al.
Published: (2025-07-01)

Role of Immunotherapy in the Treatment of Hepatocellular Carcinoma
by: Irina Y. Dobrosotskaya, et al.
Published: (2025-04-01)

Novel Insights Into Receptor Tyrosine Kinases in Pulmonary Arterial Hypertension
by: Wenze Wu, et al.
Published: (2025-08-01)

The effect of exercise intervention on angiogenesis gene expression (inducing and inhibiting factors) following myocardial ischemia-reperfusion
by: Y Mehrialvar, et al.
Published: (2017-10-01)

Therapeutic targeting of protein arginine methyltransferases reduces breast cancer progression by disrupting angiogenic pathways
by: Kamohelo Maphalala, et al.
Published: (2025-09-01)

The inhibitory effect of tyrosine kinase inhibitors on angiogenesis in zebrafish and interrelationship with the activation of the PI3K/AKT pathway
by: Lili Yang, et al.
Published: (2025-08-01)

Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer
by: Xiaosong Li, et al.
Published: (2025-07-01)

Osteosarcoma: current insights and advances
by: Guraustin S. Brar, et al.
Published: (2025-06-01)

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication
by: Yulong Han, et al.
Published: (2025-11-01)

Relapsed Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia responds well to a combination of modified hyper‐CVAD, blinatumomab and tyrosine kinase inhibitor
by: Gaétan Basile, et al.
Published: (2025-02-01)

Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors
by: Nikhil Vojjala, et al.
Published: (2025-01-01)

The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature
by: Abdulrahman Al‐Abdulmalek, et al.
Published: (2023-03-01)

Factors of angiogenesis in the development of physiological and pathological processes of the female gonads
by: V. G. Zenkina
Published: (2016-10-01)

Evaluating the impact of COVID-19 on cancer care: a comprehensive analysis of treatment modifications, risk factors, and patient outcomes
by: Xuquan Jing, et al.
Published: (2025-06-01)

Combined Use of Cabozantinib and Nivolumab in Clinical Practice
by: V. E. Askarov, et al.
Published: (2024-04-01)

Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases
by: Vanda Salutari
Published: (2025-06-01)

Interdisciplinary approach to the management of patients with uterine cancer progression
by: K. Yu. Morkhov, et al.
Published: (2022-05-01)

Prognostic Correlation of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor with Radiological Tumor Size in Pediatric Nephroblastoma and Neuroblastoma: A Prospective Study
by: Pujana Kanneganti, et al.
Published: (2025-01-01)

PGF2α facilitates pathological retinal angiogenesis by modulating endothelial FOS‐driven ELR+ CXC chemokine expression
by: Yan Zhao, et al.
Published: (2022-12-01)

Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer
by: Leslie Cheng, et al.
Published: (2025-02-01)

Angiogenic Factors and Inflammatory Bowel Diseases
by: Zhiru Li, et al.
Published: (2025-05-01)

COVID19 infection and vascular rearrangement/ controlled angiogenesis – A new supportive therapeutic approach in patients with pre-existing ischemic and high-shear vascular conditions
by: Debatosh Datta, et al.
Published: (2020-01-01)

Establishment of in vitro Src tyrosine kinase inhibitors screening model
by: WANG Chen-hui, et al.
Published: (2007-11-01)

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
by: Raji E Joseph, et al.
Published: (2024-12-01)

Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma
by: Alexander Scholz, et al.
Published: (2015-12-01)

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies
by: Tara Murty, et al.
Published: (2025-06-01)

Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors
by: GA Gusarova, et al.
Published: (2016-10-01)

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01)

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01)

Incidence Status and Factors Associated With Tyrosine Kinase Inhibitor‐Induced Hypertension in Patients With Renal Cell Carcinoma
by: Satoru Nakanishi, et al.
Published: (2025-05-01)

Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma
by: Shengyuan Xu, et al.
Published: (2025-05-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
by: Masato Kikuta, et al.
Published: (2025-01-01)

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study
by: Joohyun Hong, et al.
Published: (2024-03-01)

Angiogenesis in rheumatoid Arthritis: Pathological characterization, pathogenic mechanisms, and nano-targeted therapeutic strategies
by: Fang Zhao, et al.
Published: (2025-08-01)